STAGE IVB PROSTATE CANCER AJCC V8

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and has stopped responding to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can shr…

This study looks at whether men with metastatic prostate cancer that responds extremely well to hormone therapy can safely take a break from treatment. The goal is to see if their testosterone levels can recover and how long they can stay off therapy without the cancer worsening.…

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests whether a special PET scan (PSMA PET) can help pick the right patients for radium-223 (Ra-223) radiation therapy. Ra-223 targets bone tumors in men with castration-resistant prostate cancer that has spread to the bones. The goal is to see if using the scan leads …

This study tests whether adding the drug relugolix to standard radiation therapy can delay cancer growth in men with prostate cancer that has spread to a few other body spots. Relugolix lowers testosterone, which some cancer cells need to grow. About 194 men will receive either r…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. It tests two drugs together: olaparib, which stops cancer cells from repairing themselves, and radium-223, a radioactive drug that targets bone tu…

This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naive prostate cancer that has spread. The goal is to see how long patients can stay on treatment and how well it controls the cancer. Participants must have high-risk featur…

This study tests a combination of hormone therapy (leuprolide, apalutamide, abiraterone) and precise radiation (SBRT) in 28 men whose prostate cancer has returned and spread to a few spots. The goal is to see if this approach can lower PSA levels to nearly undetectable. Participa…

This study tests a two-drug combination (niraparib/abiraterone plus prednisone) in men with a specific genetic change (SPOP mutation) in their advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the drugs can shrink t…

This study tests a combination of three drugs (apalutamide, abiraterone, and prednisone) given after chemotherapy for men with advanced prostate cancer that has spread and hasn't been treated before. The goal is to see if this approach can lower PSA levels more effectively and al…

This study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…

This study tests a special PET scan called 68Ga-PSMA-11 to see if it can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer that has come back or spread will get this scan. The goal is to see if the scan changes how doctors plan treatment, s…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…